Bisphosphonate-related osteonecrosis of the jaws: A potential alternative to drug holidays

General Dentistry

Volumn 61, Issue 5, 2013, Pages 33-38

  Damm, Douglas D ^a   Jones, David M ^b  

^a UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

^b NONE

Author keywords

Aminobisphosphonate; Bisphosphonate related osteonecrosis; Drug holiday; Jaw; Oral and maxillofacial pathology

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; RISEDRONIC ACID;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DISEASES, METABOLIC; BONE REMODELING; CASE REPORT; DENTAL PROCEDURE; DENTAL PULP DISEASES; FEMALE; FIXED PARTIAL DENTURE; FOLLOW UP; HUMAN; MANDIBULAR DISEASES; ORAL SURGERY; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOPOROSIS; PATIENT CARE; PATIENT CARE PLANNING; PHYSIOLOGY; PROCEDURES; ROOT CARIES; TOOTH EXTRACTION;

AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; DENTAL CARE FOR CHRONICALLY ILL; DENTAL PULP DISEASES; DENTURE, PARTIAL, FIXED; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MANDIBULAR DISEASES; ORAL SURGICAL PROCEDURES; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOPOROSIS; PATIENT CARE PLANNING; PATIENT CARE TEAM; ROOT CARIES; TOOTH EXTRACTION;

EID: 84881524724     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hellstein JW, Adler RA, Edwards, E, et al. Managing the care of patients receiving antiresorptive therapy for the prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243-1251.
2. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: recommendations from the American Dental Association Council on Scientific Affairs. Available at: http://www.aae.org/uploadedFiles/Publications-and-Research/Endodontics-Colleagues-for-Excellence-Newsletter/BONJ-ADA-Report.pdf. Accessed May 6, 2011.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527-534.
4. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567-1575.
5. Palmer RM, Saywell RM Jr, Zollinger TW, et al. The impact of the prospective payment system on the treatment of hip fractures in the elderly. Arch Intern Med. 1989;149(10):2237-2241.
6. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319): 1761-1767.
7. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86(11):1022-1033.
8. Doll B, Aleef M, Hollinger JO. Overview of fracture repair. In: Pietrzak WS, ed. Orthopedic Biology and Medicine: Musculoskeletal Tissue Regeneration, Biological Materials and Methods. Totowa, NJ: Humana Press; 2008:39-61.
9. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem. 1994;55(3):273-286.
10. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW. The osteocyte. Int J Biochem Cell Biol. 2004;36(1):1-8.
11. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3(3):211-237.
12. Martin RB, Burr DB, Sharkey NA. Skeletal Tissue Mechanics. New York, NY: Springer-Verlag Inc; 1998:84.
13. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12.
14. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofacial Surg. 2007;65(12):2397-2410.
15. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
16. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures. JAMA. 2011;305(8):783-789.
17. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006;61(1): 31-33.
18. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4): 1555-1565.
19. Amgen, Inc. Prolia [prescribing information]. Available at: http://pi.amgen.com/united-states/prolia/prolia-pi.pdf. Accessed May 6, 2013.
20. Diz P, Lopez-Cedrun JL, Arenaz J, Scully C. Denosumabrelated osteonecrosis of the jaw. J Am Dent Assoc. 2012;143(9):981-984.
21. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castrationresistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379(9810):39-46. Comment in: Kyrgidis A, Tzellos TG. Denosumab in castration-resistant prostate cancer. Lancet. 2012;379(9828):e50, Author reply: e50-e51.
22. Amgen Inc. Xgeva [prescribing information]. Available at: http://pi.amgen.com/united-states/xgeva/xgeva-pi.pdf. Accessed May 6, 2013.
23. Eli Lilly and Company. Forteo [prescribing information]. Available at: http://pi.lilly.com/us/forteo-pi.pdf. Accessed May 6, 2013.
24. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115-137.
25. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1-34)]. J Oral Maxillofac Surg. 2007;65(3): 573-580.
26. Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med. 2010;363(25):2473-2474.
27. Novartis Pharmaceuticals Corporation. Reclast [prescribing information]. Available at: http://www.pharma. us.novartis.com/product/pi/pdf/reclast.pdf. Accessed May 6, 2013.